Novartis AG Statistics
Total Valuation
Novartis AG has a market cap or net worth of $292.89 billion. The enterprise value is $333.71 billion.
| Market Cap | 292.89B |
| Enterprise Value | 333.71B |
Important Dates
The next confirmed earnings date is Tuesday, October 27, 2026, before market open.
| Earnings Date | Oct 27, 2026 |
| Ex-Dividend Date | Mar 11, 2026 |
Share Statistics
Novartis AG has 1.90 billion shares outstanding. The number of shares has decreased by -2.69% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.90B |
| Shares Change (YoY) | -2.69% |
| Shares Change (QoQ) | -0.47% |
| Owned by Insiders (%) | 0.11% |
| Owned by Institutions (%) | 36.08% |
| Float | 1.86B |
Valuation Ratios
The trailing PE ratio is 23.85 and the forward PE ratio is 16.11.
| PE Ratio | 23.85 |
| Forward PE | 16.11 |
| PS Ratio | 5.11 |
| Forward PS | 4.92 |
| PB Ratio | 7.80 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 18.71 |
| P/OCF Ratio | 16.91 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 16.68, with an EV/FCF ratio of 21.31.
| EV / Earnings | 33.27 |
| EV / Sales | 5.82 |
| EV / EBITDA | 16.68 |
| EV / EBIT | 21.47 |
| EV / FCF | 21.31 |
Financial Position
The company has a current ratio of 0.88, with a Debt / Equity ratio of 1.29.
| Current Ratio | 0.88 |
| Quick Ratio | 0.58 |
| Debt / Equity | 1.29 |
| Debt / EBITDA | 2.41 |
| Debt / FCF | 3.09 |
| Interest Coverage | 9.85 |
Financial Efficiency
Return on equity (ROE) is 24.33% and return on invested capital (ROIC) is 15.36%.
| Return on Equity (ROE) | 24.33% |
| Return on Assets (ROA) | 8.66% |
| Return on Invested Capital (ROIC) | 15.36% |
| Return on Capital Employed (ROCE) | 18.36% |
| Weighted Average Cost of Capital (WACC) | 6.22% |
| Revenue Per Employee | $762,140 |
| Profits Per Employee | $133,272 |
| Employee Count | 75,267 |
| Asset Turnover | 0.51 |
| Inventory Turnover | 2.29 |
Taxes
In the past 12 months, Novartis AG has paid $2.63 billion in taxes.
| Income Tax | 2.63B |
| Effective Tax Rate | 20.80% |
Stock Price Statistics
The stock price has increased by +17.99% in the last 52 weeks. The beta is 0.47, so Novartis AG's price volatility has been lower than the market average.
| Beta (5Y) | 0.47 |
| 52-Week Price Change | +17.99% |
| 50-Day Moving Average | 148.17 |
| 200-Day Moving Average | 151.49 |
| Relative Strength Index (RSI) | 61.14 |
| Average Volume (20 Days) | 1,932,825 |
Short Selling Information
The latest short interest is 5.62 million, so 0.30% of the outstanding shares have been sold short.
| Short Interest | 5.62M |
| Short Previous Month | 5.63M |
| Short % of Shares Out | 0.30% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.15 |
Income Statement
In the last 12 months, Novartis AG had revenue of $57.36 billion and earned $10.03 billion in profits. Earnings per share was $6.45.
| Revenue | 57.36B |
| Gross Profit | 43.05B |
| Operating Income | 15.54B |
| Pretax Income | 12.64B |
| Net Income | 10.03B |
| EBITDA | 20.01B |
| EBIT | 15.54B |
| Earnings Per Share (EPS) | $6.45 |
Balance Sheet
The company has $8.98 billion in cash and $48.31 billion in debt, with a net cash position of -$39.34 billion or -$20.75 per share.
| Cash & Cash Equivalents | 8.98B |
| Total Debt | 48.31B |
| Net Cash | -39.34B |
| Net Cash Per Share | -$20.75 |
| Equity (Book Value) | 37.56B |
| Book Value Per Share | 19.64 |
| Working Capital | -3.78B |
Cash Flow
In the last 12 months, operating cash flow was $17.33 billion and capital expenditures -$1.67 billion, giving a free cash flow of $15.66 billion.
| Operating Cash Flow | 17.33B |
| Capital Expenditures | -1.67B |
| Depreciation & Amortization | 4.47B |
| Net Borrowing | 16.19B |
| Free Cash Flow | 15.66B |
| FCF Per Share | $8.26 |
Margins
Gross margin is 75.05%, with operating and profit margins of 27.09% and 17.49%.
| Gross Margin | 75.05% |
| Operating Margin | 27.09% |
| Pretax Margin | 22.04% |
| Profit Margin | 17.49% |
| EBITDA Margin | 34.88% |
| EBIT Margin | 27.09% |
| FCF Margin | 27.29% |
Dividends & Yields
This stock pays an annual dividend of $3.08, which amounts to a dividend yield of 2.00%.
| Dividend Per Share | $3.08 |
| Dividend Yield | 2.00% |
| Dividend Growth (YoY) | 18.68% |
| Years of Dividend Growth | 6 |
| Payout Ratio | 47.28% |
| FCF Payout Ratio | 34.94% |
| Buyback Yield | 2.69% |
| Shareholder Yield | 4.69% |
| Earnings Yield | 4.19% |
| FCF Yield | 5.35% |
Analyst Forecast
The average price target for Novartis AG is $154.65, which is 0.55% higher than the current price. The consensus rating is "Hold".
| Price Target | $154.65 |
| Price Target Difference | 0.55% |
| Analyst Consensus | Hold |
| Analyst Count | 12 |
| Revenue Growth Forecast (3Y) | 4.74% |
| EPS Growth Forecast (3Y) | 6.39% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 11, 2000. It was a forward split with a ratio of 2:1.
| Last Split Date | May 11, 2000 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 5 |